title: The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes.
abstract: We previously reported that metformin improves insulin-mediated glucose liver metabolism in patients with non insulin dependent diabetes (NIDDM). It is not clear whether this is a direct effect of metformin on liver metabolism or mediated by other mechanisms such as increased liver blood flow. In this respect it has recently been reported that metformin increases hepatic blood flow (HBF) in diabetic rats. The aim of this study was to evaluate whether the administration of metformin is associated with modifications in HBF in humans. Patients affected by NIDDM (n = 11) and normal subjects (n = 6) were studied. In the first protocol HBF was investigated in six overweight (BMI 27 +/- 2 Kg/m2) NIDDM patients and six normal subjects (age and BMI matched) already on metformin treatment before and 2 h after the administration of 500 mg metformin. In the second protocol HBF was investigated in obese (BMI 32 +/- 1 Kg/m2) NIDDM patients (n = 5) in good metabolic control before and after 15 days of metformin at the dose of 1 g daily. HBF was measured by intravenous injection of 3 mCi 99mTc-phytate. In both protocols no significant changes in HBF were observed following metformin administration either in NIDDM patients or normal subjects. No significant differences were observed in HBF between diabetic patients and normal subjects. These data indicate that metformin has no effect on HBF in man. The previously reported improvement of insulin mediated liver metabolism induced by metformin is likely to be a consequence of the direct effect of the drug at hepatocyte level which is independent of HBF modifications.
authors.affiliation: Gruppo Nu.M.E.D. Servizio Speciale di Medicina Nucleare, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Signore
authors.forename: V
authors.initials: V
authors.lastname: Fiore
authors.forename: M
authors.initials: M
authors.lastname: Chianelli
authors.forename: E
authors.initials: E
authors.lastname: Procaccini
authors.forename: R
authors.initials: R
authors.lastname: Barone
authors.forename: G
authors.initials: G
authors.lastname: Ronga
authors.forename: M
authors.initials: M
authors.lastname: Negri
authors.forename: P
authors.initials: P
authors.lastname: Pozzilli
mesh_terms: D000328:Adult; D000368:Aged; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D008102:Liver Circulation / Q000187:drug effects*; D008687:Metformin / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009765:Obesity; D018579:Patient Selection; D015203:Reproducibility of Results
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin